Myeloproliferative Neoplasms

Blast-Phase MPNs: One-Third Achieve Long-Term Survival with Allogeneic Transplantation

By MedXY 04/21/2026

Allogeneic hematopoietic stem cell transplantation offers a potential cure for blast-phase myeloproliferative neoplasms, with one-third of patients achieving long-term survival. Key factors influencing outcomes include TP53 mutations and peripheral blast burden.

Hematology-Oncology news

Selective JAK2 Inhibition OB756 Shows Promise in Hydroxyurea/Interferon‑Intolerant or -Resistant Essential Thrombocythemia

By MedXY 11/01/2025

A Phase II multicenter study reports that OB756, a selective JAK2 inhibitor, is active and reasonably well tolerated in hydroxyurea- or interferon-intolerant/resistant essential thrombocythemia, producing platelet and leukocyte control, spleen volume reduction, symptom improvement and reductions in JAK2 V617F allele burden.

Hematology-Oncology news

Genetic Architecture of Myeloproliferative Neoplasm Subtypes: Uncovering a Novel Sex-Specific Association at CDH22/CD40

By MedXY 10/14/2025

A large genome-wide analysis identifies multiple genetic loci influencing MPN subtypes and reveals a female-specific variant at CDH22/CD40, enhancing understanding of disease heterogeneity and potential for personalized risk stratification.